



MIDWEST

CEPAC

COMPARATIVE EFFECTIVENESS
PUBLIC ADVISORY COUNCIL

Ifezuntrigene Inilparvovec (AMT-130) for

Huntington's Disease: Public Meeting

Thursday • March 25, 2027 • 10:00am CT

Draft Virtual Meeting Agenda

Connect with ICER on our social media channels



10:00 AM – 10:20 AM CT	Meeting Convened and Opening Remarks Sarah K. Emond, MPP, President and CEO, ICER
10:20 AM – 11:00 AM CT	Presentation of the Clinical Evidence Grace Lin, MD, MAS, Medical Director for Health Technology Assessment, ICER, Associate Professor of Medicine and Health Policy, UCSF
11:00 AM – 11:40 AM CT	Presentation of the Economic Model Linda Luu, MSc, Research Scientist, Department of Pharmacy, University of Washington
11:40 AM – 11:50 AM CT	Manufacturer Comments and Discussion
11:50 AM – 12:00 PM CT	Public Comments and Discussion
12:00 PM – 12:50 PM CT	Lunch Break
12:50 PM – 1:50 PM CT	Midwest CEPAC Vote on Clinical Effectiveness and Value Moderator: Rachel Sachs, JD, MPH, Professor of Law, Washington University in St. Louis
1:50 PM – 2:00 PM CT	Break
2:00 PM – 3:30 PM CT	Policy Roundtable Moderator: Sarah K. Emond, MPP, President and CEO, ICER
3:30 PM – 4:00 PM CT	Reflections from Midwest CEPAC
4:00 PM CT	Meeting Adjourned